Aripiprazole-induced Sleep-related Eating Disorder Aripiprazole-induced Sleep-related Eating Disorder
This case of sleep-related eating disorder in a patient taking aripiprazole for depression suggests that this disorder should be considered as a potential side effect of this drug.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2018 Category: Consumer Health News Tags: Psychiatry Journal Article Source Type: news

Aripiprazole Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - June 5, 2018 Category: Drugs & Pharmacology Source Type: news

Antipsychotic May Fuel Urge to Gamble Antipsychotic May Fuel Urge to Gamble
An updated literature review provides more evidence of an association between gambling disorder and the second-generation atypical antipsychotic aripiprazole.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

One-Day Injectable Aripiprazole Tx Passes Test
(MedPage Today) -- Results comparable to traditional 21-day oral regimen (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 8, 2018 Category: Primary Care Source Type: news

The Drugs That Changed Our Minds by Lauren Slater – review
Twenty years after hailing antidepressants in her memoir Prozac Diary, a now jaded, sceptical Lauren Slater revisits the psychopharmacological industry – with uneven resultsInProzac Diary (1998), Lauren Slater wrote powerfully of the way fluoxetine had transformed her previously chaotic life. While the author recorded a handful of negative side-effects – a profound loss of libido, for instance – the reader was left with the sense that Prozac had pieced back together the shards of Slater’s existence. In some ways,The Drugs That Changed Our Minds is a sequel to that book. Slater is now in her mid-50s,...
Source: Guardian Unlimited Science - April 1, 2018 Category: Science Authors: Alex Preston Tags: Autobiography and memoir Science and nature Books Medical research Depression Society Culture Source Type: news

Proteus CMO talks regulation hurdles, future plans for digital pill
It ’s still the early days, but the FDA’s approval of Proteus Digital Health and Otsuka Pharmaceuticals’ Abilify MyCite has changed the discussion of digital technology in healthcare. (Source: mobihealthnews)
Source: mobihealthnews - March 8, 2018 Category: Information Technology Source Type: news

Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation) - Ostinelli EG, Jajawi S, Spyridi S, Sayal K, Jayaram MB.
BACKGROUND: People experiencing psychosis may become aggressive. Antipsychotics, such as aripiprazole in intramuscular form, can be used in such situations. OBJECTIVES: To evaluate the effects of intramuscular aripiprazole in the treatment of psych... (Source: SafetyLit)
Source: SafetyLit - January 15, 2018 Category: International Medicine & Public Health Tags: Occupational Issues Source Type: news

Pharma news in clinical trials, chronic condition management, and innovation from Q4 2017
Digital health in pharma definitely had a milestone moment in the fourth quarter with the FDA approval of Abilify MyCite, a new, sensor-enabled version of Otsuka ’s drug for schizophrenia powered by Proteus Digital Health’s ingestible sensor technology. In addition to that, the quarter saw numerous other moves by pharma companies around clinical trials, chronic disease management, mental health, and, more generally, innovation. (Source: mobihealthnews)
Source: mobihealthnews - December 27, 2017 Category: Information Technology Source Type: news

Gene Polymorphisms and Aripiprazole-induced Autonomic Dysfunction Gene Polymorphisms and Aripiprazole-induced Autonomic Dysfunction
Certain polymorphisms in the ABCB1 gene appear to be linked to aripiprazole-induced autonomic nervous system dysfunction in patients with schizophrenia, researchers from Japan report.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 20, 2017 Category: Pathology Tags: Psychiatry News Source Type: news

New FDA-approved "trackable" pill transmits information it will tattle on you if you don't take your meds
(Natural News) The U.S. Food and Drug Administration (FDA) recently approved a digital pill embedded with a sensor designed to inform physicians whether their patients are taking their medications. The federal approval marks a growing trend towards addressing drug non-adherence among patients, according to a New York Times report. The pill, called Abilify MyCite, is a modified version... (Source: NaturalNews.com)
Source: NaturalNews.com - December 13, 2017 Category: Consumer Health News Source Type: news

Abilify MyCite (Aripiprazole Tablets with Sensor) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 27, 2017 Category: Drugs & Pharmacology Source Type: news

In-Depth: How digital sensors could change the face of pharma
Earlier this week, Proteus Digital Health and Otsuka Pharmaceuticals announced that Abilify MyCite, a new, sensor-enabled version of Otsuka ’s drug for schizophrenia, had received FDA approval for mental health conditions including schizophrenia and bipolar disorder. (Source: mobihealthnews)
Source: mobihealthnews - November 17, 2017 Category: Information Technology Source Type: news

FDA Approves First Pill with Digital Tracker
The FDA has approved a new version of the antipsychotic aripiprazole embedded with a digital sensor to allow patients to track when the medication was... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 15, 2017 Category: Primary Care Source Type: news

Digital pill could address a "big problem" with medication
CBS News chief medical correspondent Dr. Jon LaPook explains how the digital pill, Abilify MyCite, works (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 15, 2017 Category: Consumer Health News Source Type: news

Otsuka, Proteus finally win FDA approval for sensor-equipped Abilify
The first drug in the US with a digital ingestion tracking system has been approved by the FDA. The pill, Abilify MyCite, is prescribed for treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and as an add-on treatment for depression in adults. (Source: mobihealthnews)
Source: mobihealthnews - November 14, 2017 Category: Information Technology Source Type: news

FDA approves first trackable pill that syncs with a phone
The FDA approved a pill that tracks when patients take their prescribed psychiatric drug. The medication, Abilify MyCite, is a variation on a drug used to treat schizophrenia and bipolar disorder. (Source: the Mail online | Health)
Source: the Mail online | Health - November 14, 2017 Category: Consumer Health News Source Type: news

FDA Clears Drug With Ingestible Digital Tracker FDA Clears Drug With Ingestible Digital Tracker
Abilify MyCite is the first drug approved in the United States that has a digital tracking system for patients and providers to monitor medication intake.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

'Digital Pill' Lets Doctors Know It's Been Taken
The U.S. Food and Drug Administration has given the nod to Abilify MyCite, for use in patients with schizophrenia, an add-on treatment for depression, and to help control episodes of either manic or "mixed" episodes for people with bipolar disorder. (Source: WebMD Health)
Source: WebMD Health - November 14, 2017 Category: Consumer Health News Source Type: news

FDA OKs First 'Digital Pill' That Lets Doctors Know It's Been Taken
The U.S. Food and Drug Administration has given the nod to Abilify MyCite, for use in patients with schizophrenia, an add-on treatment for depression, and to help control episodes of either manic or "mixed" episodes for people with bipolar disorder. (Source: WebMD Health)
Source: WebMD Health - November 14, 2017 Category: Consumer Health News Source Type: news

FDA approves first pill with sensor to track ingestion
The FDA today approved Abilify MyCite, the first drug in the U.S. to have an ingestible sensor embedded within the pill that can track if the medication was taken. The drug-device combination product is indicated for the treatment of schizophrenia, acute treatment of manic and mixed episodes linked with bipolar I disorder and as an add-on treatment for depression in adults. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves first pill with sensor to track ingestion appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Neurological Patient Monitoring Pharmaceuticals Regulatory/Compliance Wall Street Beat Otsuka Pharmaceutical Proteus Digital Health Source Type: news

' Digital Pill', Abilify Mycite, Tells Doctor When Patient Takes It
TUESDAY, Nov. 14, 2017 -- The first drug designed to alert a doctor when a patient takes the medication has been approved by the U.S. Food and Drug Administration. Abilify MyCite (aripiprazole with sensor) has an embedded sensor that sends a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 14, 2017 Category: General Medicine Source Type: news

FDA OKs First'Digital Pill', Abilify Mycite, That Lets Doctors Know It's Been Taken
TUESDAY, Nov. 14, 2017 -- Offering both the promise of better patient compliance with health care, but also fears of a medical " Big Brother, " a newly approved " digital pill " allows physicians to track whether or not it's been ingested by... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 14, 2017 Category: General Medicine Source Type: news

FDA approves first drug in U.S. with digital ingestion tracking
(Reuters) - The U.S. Food and Drug Administration said on Monday that it had approved Otsuka Pharmaceutical Co Ltd's Abilify MyCite, the first drug with a digital ingestion tracking system to be approved in the United States. (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves pill with sensor that digitally tracks if patients have ingested their medication
The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 14, 2017 Category: American Health Source Type: news

FDA Approves Pill with Sensor that Digitally Tracks if Patients Have Ingested their Medication
The U.S. Food and Drug Administration has approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults. (Source: eHealth News EU)
Source: eHealth News EU - November 14, 2017 Category: Information Technology Tags: Featured Development Research and Development Source Type: news

FDA approves pill with sensor that digitally tracks if patients have ingested their medication
The U.S. Food and Drug Administration has approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults. (Source: World Pharma News)
Source: World Pharma News - November 14, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication
November 13, 2017 -- The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 13, 2017 Category: Drugs & Pharmacology Source Type: news

Aripiprazole May Reduce Cocaine Cravings in People With Schizophrenia Aripiprazole May Reduce Cocaine Cravings in People With Schizophrenia
In people with schizophrenia, the dopamine modulator aripiprazole appears to reduce cocaine cravings better than the dopamine blocker perphenazine after an acclimation period, according to a small, double-blind randomized trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 2, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Otsuka taps Medibio's quantitative mental health assessment for Abilify
Otsuka, the Japanese pharma company that makes the antipsychotic drug Abilify, has partnered with Australian digital health company Medibio to use Medibio ’s system to assess the efficacy of its flagship product. Medibio uses wearable-derived data about heart rate, motion, and sleep to create objective biomarkers for mental illness. (Source: mobihealthnews)
Source: mobihealthnews - October 10, 2017 Category: Information Technology Source Type: news

Abilify vs. Invega
Title: Abilify vs. InvegaCategory: MedicationsCreated: 9/29/2017 12:00:00 AMLast Editorial Review: 9/29/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - September 29, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Issues Warning About Mixing Opioid Addiction Treatments With Other Meds
TRENTON, N.J. (AP) — The Food and Drug Administration issued new warnings Wednesday about the dangers of combining medication for opioid addiction with anti-anxiety medicines and other drugs that also slow breathing and brain activity. The FDA warned that mixing such drugs can cause difficulty breathing, coma or death, so it should be done with caution. The agency said a growing number of people fighting opioid addiction with methadone or buprenorphine also take other prescription drugs that slow action of the central nervous system. The warning lists several dozen brand-name and generic drugs that could be risky, in...
Source: JEMS Patient Care - September 20, 2017 Category: Emergency Medicine Authors: Linda A. Johnson, Associated Press Tags: Patient Care News Source Type: news

FDA Issues Warning About Mixing Opioid Addiction Treatments With Other Meds
TRENTON, N.J. (AP) — The Food and Drug Administration issued new warnings Wednesday about the dangers of combining medication for opioid addiction with anti-anxiety medicines and other drugs that also slow breathing and brain activity. The FDA warned that mixing such drugs can cause difficulty breathing, coma or death, so it should be done with caution. The agency said a growing number of people fighting opioid addiction with methadone or buprenorphine also take other prescription drugs that slow action of the central nervous system. The warning lists several dozen brand-name and generic drugs that could be risky, in...
Source: JEMS: Journal of Emergency Medical Services News - September 20, 2017 Category: Emergency Medicine Authors: Linda A. Johnson, Associated Press Tags: Patient Care News Source Type: news

FDA Issues Warning About Mixing Opioid Addiction Treatments With Other Meds
TRENTON, N.J. (AP) — The Food and Drug Administration issued new warnings Wednesday about the dangers of combining medication for opioid addiction with anti-anxiety medicines and other drugs that also slow breathing and brain activity. The FDA warned that mixing such drugs can cause difficulty breathing, coma or death, so it should be done with caution. The agency said a growing number of people fighting opioid addiction with methadone or buprenorphine also take other prescription drugs that slow action of the central nervous system. The warning lists several dozen brand-name and generic drugs that could be risky, in...
Source: JEMS Patient Care - September 20, 2017 Category: Emergency Medicine Authors: Linda A. Johnson, Associated Press Tags: Patient Care News Source Type: news

Monthly Injected Schizophrenia Drug Has Modest Metabolic Effects Monthly Injected Schizophrenia Drug Has Modest Metabolic Effects
Patients show small changes in weight and metabolic parameters from long-term treatment with injectable aripiprazole lauroxil (AL), new research shows.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Overdoses with aripiprazole: signs, symptoms and outcomes in 239 exposures reported to the Danish Poison Information Center - Christensen AP, Boegevig S, Christensen MB, Petersen KM, Dalhoff KP, Petersen TS.
The aim of this study was to characterize the clinical signs and symptoms of exposures to aripiprazole overdoses. We retrospectively identified all aripiprazole exposures reported to the Danish Poisons Information Center (DPIC) from June 2007 to May 2015. ... (Source: SafetyLit)
Source: SafetyLit - September 9, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

ReCor Medical adds another $12m for trial of Paradise renal denervation device
ReCor Medical last week added a $12 million contribution from Otsuka Pharmaceutical (TYO:4578) to the $10 million it raised from the Japanese conglomerate last year for a clinical trial of its Paradise renal denervation device for treating hypertension, ReCor president & CEO Andrew Weiss told MassDevice.com this morning. In May 2016 Otsuka participated in a strategic investment of an unspecified amount; Weiss told us that that round and the $12 million debt financing added last week are earmarked for the Radiance-HTN efficacy study of the Paradise device, which is designed to use ultrasoun...
Source: Mass Device - August 16, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Funding Roundup Wall Street Beat Hypertension ReCor Medical Source Type: news

Injectable, extended-release bipolar drug wins FDA nod
Otsuka Pharmaceutical (TYO:4578) and Lundbeck said last week that its extended-release injectable aripiprazole suspension, Abilify Maintena, won FDA approval as a maintenance monotherapy for adults with bipolar I disorder. The once-monthly intramuscular formulation was created by Otsuka and co-developed and commercialized with Lundbeck, the companies reported. Get the full story at our sister site, Drug Delivery Business News. The post Injectable, extended-release bipolar drug wins FDA nod appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat Lundbeck Otsuka Pharmaceutical Source Type: news

FDA Approves Long-acting Injectable for Bipolar Disorder FDA Approves Long-acting Injectable for Bipolar Disorder
The FDA has approved extended-release injectable aripiprazole for maintenance monotherapy for bipolar disorder in adults.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 31, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

Abilify Maintena (aripiprazole) for Extended-Release Injectable Suspension Approved by the U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder
Valby, Denmark and Tokyo, Japan, 28 July 2017 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced Abilify Maintena ® (aripiprazole) for extended-release injectable suspension was approved by the U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 28, 2017 Category: Drugs & Pharmacology Source Type: news

Addition of Aripiprazole Ups Major Depressive Disorder Remission
Small increased likelihood of remission at 12 weeks in patients with major depressive disorder (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - July 12, 2017 Category: Psychiatry Tags: Family Medicine, Geriatrics, Internal Medicine, Nursing, Pharmacy, Psychiatry, Journal, Source Type: news

For Treatment-Resistant Depression, Add an Antipsychotic or Switch Antidepressants? (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM For patients with depression unresponsive to antidepressants, adding the antipsychotic aripiprazole seems modestly better than switching to the antidepressant bupropion, a JAMA study … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 12, 2017 Category: Primary Care Source Type: news

Study compares switching meds vs. an additional med for patients unresponsive to an antidepressant
(The JAMA Network Journals) Among patients unresponsive to an antidepressant medication, adding the antipsychotic aripiprazole modestly increased the likelihood of remission from depression compared to switching to the antidepressant bupropion, according to a study published by JAMA. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 11, 2017 Category: International Medicine & Public Health Source Type: news

Antipsychotics Have Side Effects, Limited Value in Pediatric Psychosis Antipsychotics Have Side Effects, Limited Value in Pediatric Psychosis
For children and adolescents with first-episode psychosis, the second generation antipsychotics quetiapine extended release and aripiprazole have equivalent efficacy, but different side effect profiles, according to a head-to-head comparison.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

FDA Approves Longer-Acting Aripiprazole for Schizophrenia FDA Approves Longer-Acting Aripiprazole for Schizophrenia
The FDA has approved a 2-month dose of aripiprazole lauroxil extended-release injectable suspension for the treatment of schizophrenia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

FDA Approves Two-Month Aristada for Treatment of Schizophrenia
DUBLIN--(BUSINESS WIRE)--Jun. 6, 2017-- Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 6, 2017 Category: Drugs & Pharmacology Source Type: news

Otsuka, Proteus resubmit FDA application for novel drug-device combination
One year after the FDA declined to approve Proteus Digital Health and Otsuka's new sensor-embedded formulation of Otsuka's antipsychotic drug Abilify, the companies are giving it another shot, resubmitting the application with additional information. (Source: mobihealthnews)
Source: mobihealthnews - May 23, 2017 Category: Information Technology Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 23, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Philips picks up airway clearance device dev RespirTech Royal Philips said today it inked a deal to acquire airway clearance solution developer RespirTech for an undisclosed amount. St. Paul, Minn.-based RespirTech was founded ...
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Proteus, Otsuka take another run at FDA approval for Abilify-smart pill combo
Otsuka Pharmaceutical (TYO:4578) and Proteus Digital Health said today that the FDA accepted its resubmitted new drug application for their “smart pill”. The drug-device product combines Abilify and a Proteus ingestible sensor in a single tablet. The FDA is slated to make a decision on the NDA resubmission in the 4th quarter this year. Get the full story at our sister site, Drug Delivery Business News. The post Proteus, Otsuka take another run at FDA approval for Abilify-smart pill combo appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Otsuka Pharmaceutical Proteus Digital Health Source Type: news

aripiprazole (Abilify, Abilify Maintena, Aristrada)
Title: aripiprazole (Abilify, Abilify Maintena, Aristrada)Category: MedicationsCreated: 2/17/2004 12:00:00 AMLast Editorial Review: 5/1/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 1, 2017 Category: Drugs & Pharmacology Source Type: news

Improve Your Mood With Turmeric Root (Curcumin)
"Dr. Sears," C.R. asked me, "I know curcumin is good for treating a lot of things, but can it improve someone's mood?" This morning, one of the women on my staff, C.R., came into my office to talk to me about her 15-year-old son. He'd been irritable and moody and sleeping a lot lately. Most mornings, he'd miss the bus to school and then stress about being late. But today, he was up on time with his backpack packed and a smile on his face. C.R. even heard him whistling in the shower! And he was at the bus stop 10 minutes early. C. R. started taking curcumin supplements a few weeks ago. She ha...
Source: Al Sears, MD Natural Remedies - March 21, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news